WHERE DIGITAL INNOVATION ENSURES MATERNAL DRUG SAFETY
VISION
Changing the way the world thinks about testing drugs for maternal safety
Reproductive toxicology testing for novel substances should be reproducible, efficient, accurate and secure. It should be nonbinary and allow artificial intelligence enhanced pattern recognition, predict drug interactions, and differentiate spontaneous mutations from those caused by chemical exposure.
THE DIFFERENCE
PATENTED
METHOD
Innovation behind four worldwide patents empower the digital techniques for evaluating the maternal safety profiles of drugs and chemicals. The TIO process produces quantitative data at near micron level, allowing pattern prediction and better evaluation of drug interactions. The cloud-based platform protects and stores your companies’ critical data in a secure and cost-effective manner.
WHY USE TIO
DECREASED LIABILITY EXPOSURE
Better data and better analytic tools protect from future liability. Predictive analytics suggest efficient testing for critical interactions between compounds. Owning secure data allows look back studies to update safety sheets and defend future liability claims.
The Numbers
3
COMPANIES
18K
AVAILABLE MARKET DRUGS
4
PATENTS
1.6M
PATIENTS IN NEED
